 |
Emendo Biotherapeutics
Last updated: August 02, 2024
David Baram - President & CEO
USA | Funding: $317.8M (+)
Website: http://emendobio.com/
Emendo Biotherapeutics develops gene editing platform to expand the list of diseases amenable to treatment with gene editing, resulting in a pipeline of hematology and ophthalmology programs.
Website: http://emendobio.com/
Emendo Biotherapeutics develops gene editing platform to expand the list of diseases amenable to treatment with gene editing, resulting in a pipeline of hematology and ophthalmology programs.
